The evaluation of Mastodinon efficiency in treatment of hyperprolactinemic syndrome

The clinical efficiency of Mastodinon (Bionorica) is studied in management of 33 patients (average age 34,6 years) with different menstrual disfunctions and dysmenorrhea. In 13 patients these disturbances coexisted with hyperprolactinemia. As a result of 3-month treatment with Mastodinon we noted the normalization of menstrual function in 13 of 17 patients, and the decrease in prolactin serum levels on 10 of 13 women. The prolactin decrease was followed by increase in luteinizing hormone and progesteron, as chosen for ovulatory cycle. It is found that Mastodinon has the properties of dopaminomimetics and can be concerned as the alternative for synthetic dopaminergic drug therapy (Bromocriptine etc.).